Immune cell therapy for patients with COVID-19 related pneumonia using allogenic ex vivo NK cells

Phase I clinical trial using ex vivo-expanded allogeneic donor-derived NK cells in patients with lower respiratory disease (Moderate) caused by COVID-19.

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200621047859N2

Enrollment

Registered

2020-12-29

Start date

2020-08-22

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SARS-COV-2 related pneumonia. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: Patients with resistant pneumonia caused by COVID-19 infection with acute symptoms of pneumonia who have not responded to routine treatments. This group will receiv

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Man or woman, aged 18-70 years pneumonia that is confirmed by chest imaging (glass turbidity in High-resolution computed tomography[HRCT]) Laboratory confirmation of infection (NCP, Novel Coronavirus Pneumonia) with reverse polymerase chain reaction (RT-PCR) response from any diagnostic sampling source. Ordinary transthoracic echocardiogram Adequate kidney function, which is estimated based on glomerular filtration rate (CrCl> 60) ml / min or ml per minute / 1.73 square meters, (CrCl: Creatinine Clearance)

Exclusion criteria

Exclusion criteria: Pregnancy or lactation Infection for human immunodeficiency viruses (HIV) , hepatitis B virus (HBV) or hepatitis C virus (HCV) Patients with other serious systemic diseases or malignancies Inability to provide informed consent or compliance with test conditions

Design outcomes

Primary

Measure	Time frame
Possible hypersensitivity, Allergy symptoms. Timepoint: Daily to release date. Method of measurement: Physical examinations, Vital signs and respiratory symptoms monitoring via ICU equipment's and blood tests.;Improve severe respiratory symptoms. Timepoint: Daily to release date. Method of measurement: Blood oxygen levels, respiration volume, physical examinations.;Anaphylactic shock. Timepoint: Daily to release date. Method of measurement: Physical examinations, Vital signs and respiratory symptoms monitoring via ICU equipment's and blood tests.	—

Measure

Time frame

Possible hypersensitivity, Allergy symptoms. Timepoint: Daily to release date. Method of measurement: Physical examinations, Vital signs and respiratory symptoms monitoring via ICU equipment's and blood tests.;Improve severe respiratory symptoms. Timepoint: Daily to release date. Method of measurement: Blood oxygen levels, respiration volume, physical examinations.;Anaphylactic shock. Timepoint: Daily to release date. Method of measurement: Physical examinations, Vital signs and respiratory symptoms monitoring via ICU equipment's and blood tests.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Ramin Sarrami Forooshani

Iranian academic center for education culture and research

rsf1351@gmail.com+98 21 8879 6003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 8, 2026